FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ZIMMERMAN DANIEL H
2. Issuer Name and Ticker or Trading Symbol

CEL SCI CORP [ CVM ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Senior Vice President
(Last)          (First)          (Middle)

3. Date of Earliest Transaction (MM/DD/YYYY)

9/4/2019
(Street)

 
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/4/2019    A    2375  A $7.16  112302  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ZIMMERMAN DANIEL H

 


Senior Vice President

Signatures
Daniel Zimmerman 9/5/2019
**Signature of Reporting Person Date


Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cel Sci Charts.
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cel Sci Charts.

Cel Sci Corp News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
Tuesday 23 April 2024 (5 days ago) • Business Wire
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Wednesday 20 March 2024 (1 month ago) • Business Wire
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
Form ARS - Annual Report to Security Holders
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
CEL-SCI Corporation Issues Letter to Shareholders
Thursday 7 March 2024 (2 months ago) • Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
Friday 16 February 2024 (2 months ago) • Business Wire
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 15 February 2024 (2 months ago) • Edgar (US Regulatory)
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
Wednesday 14 February 2024 (2 months ago) • Business Wire
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
Saturday 10 February 2024 (3 months ago) • Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
Wednesday 7 February 2024 (3 months ago) • Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
Thursday 1 February 2024 (3 months ago) • Business Wire
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 3 January 2024 (4 months ago) • Edgar (US Regulatory)